Navigation Links
Thyroid Stimulating Hormone Ultrasensitive

ProductsThyroid Stimulating Hormone Ultrasensitive
Company ARUP Laboratories
Item Thyroid Stimulating Hormone Ultrasensitive
Features 
Description ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' clients include more than half of the nation's university teaching hospitals and children's hospitals, major commercial laboratories, military and government facilities, and major clinics.
Info ARUP Laboratories
Customer Service: (800) 522-2787
Web site: http://www.aruplab.com

Related medicine products :

1. Free T3 EIA Thyroid Function 025-BC-1006
2. Free T4 EIA Thyroid Function 025-BC-1008
3. TPO (Ab) RIA Thyroid Function 014-HD-90.1 Thyroid Peroxidase
4. TG (Ab) EIA Thyroid Function 012-MDKAT-1 Thyroglobulin anti-tg
5. Total T4 EIA Thyroid Function 025-BC-1007
6. TPO (Ab) EIA Thyroid Function 012-MDKAM-1 Thyroid Peroxidase
7. TG (Ab) RIA Thyroid Function 014-HD 27.1 Thyroglobulin
8. Total T3 EIA Thyroid Function 025-BC-1005
9. TSH EIA Thyroid Function 025-BC-1001
10. Ultrasensitive TSH EIA Thyroid Function 025-BC-1003
11. MSTS-1 Thyroid Shield
CenterPointLock Stoma Cap
CenterPointLock Sterile Drainable Kits
CenterPointLock Non-Sterile Urostomy Kits
CenterPointLock Pre-Sized Convex FlexWear Skin Barrier
Medicine Products:
(Date:12/3/2008)...Netherlands, and LOS ANGELES, Dec. 3 /PRNewswire/ ...r as the President of Bugaboo,Americas. Boiler ha...rica for,the past 5 years. "Kari Boiler has the B...t a great team player with the vision that Bugaboo...Muis, CEO of Bugaboo International. , (Phot...
(Date:12/3/2008)...Dec. 3 The American Soc... School Student Symposium at the San Francisco Mar...8:00 a.m. PST. The symposium, which encourages an ...nd medical research, is held in conjunction with t...nts will have the opportunity to explore research ...
(Date:12/3/2008)...Dec. 3 The American Soc...essional society of blood specialists, will recogn...es and the Deputy Director of the National Heart, ...s to promote biomedical research. The Public Servi...e Society,s 50th Annual Meeting in San Francisco, ...
(Date:12/3/2008)....J., Dec. 3 MedQuist Inc. (Nasdaq:...ce Organization (MTSO) in the world, is pleased to...ial legal matters , , Resolution of the DO...d, the Company received an administrative HIPAA su...ment of Justice ("DOJ") on December 17, 2004. The ...
Breaking Medicine News(10 mins):Health News:Kari Boiler Named President of Bugaboo Americas 2Health News:ASH Holds a Special Symposium to Interest High School Students in Biomedical Research 2Health News:ASH Honors Speaker of the House Nancy Pelosi and NHLBI Deputy Director Susan Shurin, MD, for Their Public Service, Leadership, and Commitment to Biomedical Research 2Health News:ASH Honors Speaker of the House Nancy Pelosi and NHLBI Deputy Director Susan Shurin, MD, for Their Public Service, Leadership, and Commitment to Biomedical Research 3Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 2Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 3Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 4Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 5Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 6
...g less may be due to other reasons// than age itse...that had been associated with increased age for th...l at all. Instead, the findings of the research sh...olved that can lead to insomnia or lack of sleep f...
... a public notice regarding the fatal adverse event... atypical antipsychotic drugs. The notice was issu...y demented patients who were treated with the drug...7 times more likely to die than patients given pla...
...s against the general thought that chocolate is ba...te can actually improve heart function. Athens Med...ts of dark chocolate consumption on blood vessel f...lthy subjects. The scientists found that these sub...
...n of the gene involved in causing// the condition ...gia. Investigators from Yale School of Medicine ha...ngle mutation of the gene for sodium channel Nav1....from the chronic condition of primary erythromelal...
Other Medicine News:
(Date:12/3/2008)...GO, Dec. 3 Vical Incorpo...ive, binding letter of intent with EIP,Eczacibasi... of the company,s,Allovectin-7(R) immunotherapeut...public of Northern Cyprus. EIP has agreed to obtai...itory and to pay Vical upfront and milestone payme...
(Date:12/2/2008)...A, Calif., Dec. 2 TorreyPines Ther...ositive results from a 26 patient Phase II trial e... xerostomia, or dry mouth, in patients with Sjogre...a statistically significant increase in salivary f...ses: 10 mg, 15 mg, and 20 mg. These doses were saf...
(Date:12/1/2008)...LE, Md., Dec. 1 Vanda Ph...cation in The Lancet , one of the world,s leading...ts novel circadian regulator, experimental compoun...atnam et al(1) is entitled "Melatonin agonist tasi...ep-time shift: two randomised controlled multicent...
(Date:12/1/2008)...e study shows the Prox1 gene is a two-way switch t...ells to be reprogrammed so that they lose their id...s , , MEMPHIS, Tenn., Dec. 1 /PRNewswire-US...search Hospital have discovered that a certain dif...entity that it requires the constant expression of...
Breaking Medicine Technology:Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 2Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 3Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 4Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 5TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 2TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 3TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 4TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 5Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3Genomas Awarded 241 2 Million NIH SBIR Grant to Develop DNA Guided System for Management of Statin Therapy 4086 1Genomas Awarded 241 2 Million NIH SBIR Grant to Develop DNA Guided System for Management of Statin Therapy 4086 2Women at Higher Risk of Abnormal Burn Scars 14732 1Women at Higher Risk of Abnormal Burn Scars 14732 2Neuronal regulators offer potential targets for cancer 14730 1Neuronal regulators offer potential targets for cancer 14730 2NHS Choices Launches New Good Food Package 14729 1